Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus

NCT00714116

Last updated date
Study Location
Arthritis & Rheumatology Care Center
South Miami, Florida, 33143, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Systemic Lupus Erythematosus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of SLE (by greater than or equal to 4 American College of Rheumatology [ACR] Revised Criteria) greater than 6 months before study day 1.

- History of a positive antinuclear antibody (ANA) titer greater than or equal to 1:160 or equivalent.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Treatment with more than 20 mg of prednisone per day.


- Evidence of unstable clinically significant disease (e.g., cardiovascular,
cerebrovascular, respiratory, or renal disease, or any other unstable serious
disorder) other than SLE.


- History of cancer (other than resected cutaneous basal and squamous cell carcinoma or
in situ cervical cancer) with less than 5 years' documentation of a disease-free
state.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Systemic Lupus ErythematosusSubcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
NCT01405196
  1. Anniston, Alabama
  2. Anniston, Alabama
  3. Birmingham, Alabama
  4. Fair Oaks, California
  5. Lakewood, California
  6. Long Beach, California
  7. Long Beach, California
  8. Los Angeles, California
  9. Los Angeles, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. Los Angeles, California
  13. Los Angeles, California
  14. Upland, California
  15. Upland, California
  16. Daytona Beach, Florida
  17. Gainesville, Florida
  18. Gainesville, Florida
  19. Gainesville, Florida
  20. Gainesville, Florida
  21. Miami, Florida
  22. Orlando, Florida
  23. Ormond Beach, Florida
  24. Palm Harbor, Florida
  25. Pinellas Park, Florida
  26. Tampa, Florida
  27. Atlanta, Georgia
  28. Atlanta, Georgia
  29. Meridian, Idaho
  30. Chicago, Illinois
  31. Granger, Indiana
  32. Indianapolis, Indiana
  33. Indianapolis, Indiana
  34. Baltimore, Maryland
  35. Baltimore, Maryland
  36. Baltimore, Maryland
  37. Boston, Massachusetts
  38. Ann Arbor, Michigan
  39. Ann Arbor, Michigan
  40. Ann Arbor, Michigan
  41. Detroit, Michigan
  42. Saint Clair Shores, Michigan
  43. Las Vegas, Nevada
  44. Albuquerque, New Mexico
  45. Brooklyn, New York
  46. Manhasset, New York
  47. New York, New York
  48. Rochester, New York
  49. Chapel Hill, North Carolina
  50. Chapel Hill, North Carolina
  51. Chapel Hill, North Carolina
  52. Charlotte, North Carolina
  53. Charlotte, North Carolina
  54. Cleveland, Ohio
  55. Middleburg Heights, Ohio
  56. Oklahoma City, Oklahoma
  57. Wyomissing, Pennsylvania
  58. Charleston, South Carolina
  59. Jackson, Tennessee
  60. Jackson, Tennessee
  61. Dallas, Texas
  62. Dallas, Texas
  63. Houston, Texas
  64. Houston, Texas
  65. Mesquite, Texas
  66. Seattle, Washington
  67. Tacoma, Washington
  68. Clarksburg, West Virginia
  69. La Plata, Buenos Aires
  70. Rosario, Santa FE
  71. San Miguel de Tucuman, Tucuman
  72. C.a.b.a,
  73. San Juan,
  74. Santiago, Region Metropolitana
  75. Santiago, RM
  76. Santiago, RM
  77. Envigado, Antioquia, Colombia
  78. Envigado, Antioquia
  79. Medellin, Antioquia
  80. Barranquilla, Atlantico
  81. Barranquilla, Atlantico
  82. Barranquilla, Atlantico
  83. Bogota, Distrito Capital, Cundimarca
  84. Bogota, Cundinamarca
  85. Bogota, Cundinamarca
  86. Bucaramanga, Santander
  87. Bogota,
  88. Berlin,
  89. Berlin,
  90. Erlangen,
  91. Frankfurt/Main,
  92. Koeln,
  93. Leipzig,
  94. Budapest,
  95. Debrecen,
  96. Gyula,
  97. Busan,
  98. Chisinau, Md-2025
  99. San Isidro, Lima
  100. Santiago de Surco, Lima
  101. Surco, Lima
  102. Arequipa,
  103. Elblag,
  104. Poznan,
  105. Poznan,
  106. Warszawa,
  107. Rio Piedras,
  108. San Juan,
  109. Bucuresti,
  110. Bucuresti,
  111. Cluj Napoca,
  112. Galati,
  113. Taipei TOC,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Systemic Lupus ErythematosusStudy Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
NCT00714116
  1. South Miami, Florida
  2. South Miami, Florida
  3. South Miami, Florida
  4. Durham, North Carolina
  5. Duncansville, Pennsylvania
  6. Dallas, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Systemic Lupus ErythematosusStudy of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus
NCT00479622
  1. Los Angeles, California
  2. Palo Alto, California
  3. Lake Success, New York
  4. Rochester, New York
  5. Charlotte, North Carolina
  6. Columbus, Ohio
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Systemic Lupus ErythematosusA DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
NCT03845517
  1. Nadarzyn,
  2. Belgrade,
  3. Beograd,
  4. Beograd,
  5. Niska Banja,
  6. Birmingham, Alabama
  7. Birmingham, Alabama
  8. Birmingham, Alabama
  9. Birmingham, Alabama
  10. Beverly Hills, California
  11. Fullerton, California
  12. La Palma, California
  13. La Palma, California
  14. Palm Desert, California
  15. Upland, California
  16. Upland, California
  17. Denver, Colorado
  18. Bridgeport, Connecticut
  19. Stamford, Connecticut
  20. Clearwater, Florida
  21. Clearwater, Florida
  22. Gainesville, Florida
  23. Gainesville, Florida
  24. Miami Lakes, Florida
  25. Orlando, Florida
  26. Palm Harbor, Florida
  27. Saint Petersburg, Florida
  28. Tamarac, Florida
  29. Tampa, Florida
  30. Tampa, Florida
  31. Tampa, Florida
  32. Decatur, Georgia
  33. Marietta, Georgia
  34. Idaho Falls, Idaho
  35. Kansas City, Kansas
  36. Kansas City, Kansas
  37. Kansas City, Kansas
  38. Baton Rouge, Louisiana
  39. Brighton, Michigan
  40. Las Vegas, Nevada
  41. Brooklyn, New York
  42. Canton, New York
  43. Manhasset, New York
  44. New York, New York
  45. New York, New York
  46. Potsdam, New York
  47. Syracuse, New York
  48. Syracuse, New York
  49. Syracuse, New York
  50. Charlotte, North Carolina
  51. Oklahoma City, Oklahoma
  52. Bethlehem, Pennsylvania
  53. Jackson, Tennessee
  54. Memphis, Tennessee
  55. Austin, Texas
  56. Baytown, Texas
  57. Houston, Texas
  58. Spokane, Washington
  59. Kogarah, New South Wales
  60. Camberwell, Victoria
  61. Leuven,
  62. Plovdiv,
  63. Ruse,
  64. Sofia,
  65. Sofia,
  66. Rimouski, Quebec
  67. Trois-Rivieres, Quebec
  68. Medellin, Antioquia
  69. Barranquilla, Atlantico
  70. Bogotá, Cundinamarca
  71. Bucaramanga, Santander
  72. Praha 2,
  73. Paris,
  74. Paris,
  75. Paris,
  76. Pessac,
  77. Strasbourg,
  78. Berlin,
  79. Hannover,
  80. Lübeck,
  81. Mainz,
  82. Heraklion, Crete
  83. Athens,
  84. Haidari,
  85. Budapest,
  86. Debrecen,
  87. Gyula,
  88. Kitakyushu-shi, Fukuoka
  89. Asahikawa, Hokkaido
  90. Sapporo, Hokkaido
  91. Sendai, Miyagi
  92. Sasebo, Nagasaki
  93. Chuo-ku, Tokyo
  94. Shinjuku-ku, Tokyo
  95. Chiba,
  96. Fukuoka,
  97. Hiroshima,
  98. Seocho-gu, Seoul
  99. Suwon-si, Yeongtong-go
  100. Daegu,
  101. Incheon,
  102. Seoul,
  103. Mexico City, Cuauhtémoc
  104. León, Guanajuato
  105. Zapopan, Jalisco
  106. Mérida, Yucatán
  107. Chihuahua,
  108. Mexico City,
  109. Bialystok,
  110. Bydgoszcz,
  111. Lublin,
  112. Sosnowiec,
  113. Warszawa,
  114. Almada,
  115. Amadora,
  116. Coimbra,
  117. Ponte de Lima,
  118. Porto,
  119. Brasov, JUD. Brasov
  120. Cluj-Napoca, Jud. Cluj
  121. Iasi, Jud. Iasi
  122. Bucharest, Sector 1
  123. Bucuresti, Sector 1
  124. Bucuresti,
  125. Badalona,
  126. Barcelona,
  127. Barcelona,
  128. La Coruna,
  129. Sevilla,
  130. Taichung City, Taiwan (r.o.c)
  131. Kaohsiung City,
  132. Taichung,
  133. Taipei,
  134. Taipei,
  135. Kyiv,
  136. Lviv,
  137. Odesa,
  138. Odesa,
  139. Ternopil,
  140. Uzhgorod,
  141. Vinnytsia,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
Official Title  ICMJE An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Sbi-087 Administered To Subjects With Systemic Lupus Erythematosus.
Brief Summary The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SBI-087 in subjects with Systemic Lupus Erythematosus (SLE).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Lupus Erythematosus, Systemic
Intervention  ICMJE Drug: SBI-087
Single IV or SC dose of SBI-087
Study Arms  ICMJE Experimental: SBI-087
Intervention: Drug: SBI-087
Publications * Cohen S, Clowse M, Pardo P, Bhattacharya I, Menon S, Gourley I, Diehl A. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus. Clin Ther. 2016 Jun;38(6):1417-1434.e2. doi: 10.1016/j.clinthera.2016.03.028. Epub 2016 Apr 21.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 27, 2010)
30
Original Estimated Enrollment  ICMJE
 (submitted: July 8, 2008)
24
Actual Study Completion Date  ICMJE September 2012
Actual Primary Completion Date September 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of SLE (by greater than or equal to 4 American College of Rheumatology [ACR] Revised Criteria) greater than 6 months before study day 1.
  • History of a positive antinuclear antibody (ANA) titer greater than or equal to 1:160 or equivalent.

Exclusion Criteria:

  • Treatment with more than 20 mg of prednisone per day.
  • Evidence of unstable clinically significant disease (e.g., cardiovascular, cerebrovascular, respiratory, or renal disease, or any other unstable serious disorder) other than SLE.
  • History of cancer (other than resected cutaneous basal and squamous cell carcinoma or in situ cervical cancer) with less than 5 years' documentation of a disease-free state.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries Canada
 
Administrative Information
NCT Number  ICMJE NCT00714116
Other Study ID Numbers  ICMJE 3227K2-1002
B2261004 ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Emergent Product Development Seattle LLC
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date December 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP